- Results from triple combination of efti, radiotherapy and KEYTRUDA (pembrolizumab) to be presented at the Connective Tissue Oncology Society 2024 Annual Meeting
- EFTISARC-NEO is the first trial to evaluate efti in a neoadjuvant (prior to surgery) setting
- Soft tissue sarcoma is a hard-to-treat orphan disease with poor prognosis & high unmet medical need
SYDNEY, AUSTRALIA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha (efti) in combination with radiotherapy plus KEYTRUDA (pembrolizumab) for patients with soft tissue sarcoma (STS), will be presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting taking place 13-16 November 2024, in San Diego, California.
